Vanguard Group Inc Actinium Pharmaceuticals, Inc. Call Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ATNM
# of Institutions
72Shares Held
6.65MCall Options Held
369KPut Options Held
148K-
Black Rock Inc. New York, NY1.71MShares$12.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA596KShares$4.27 Million0.0% of portfolio
-
State Street Corp Boston, MA551KShares$3.94 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL231KShares$1.65 Million0.0% of portfolio
-
Verition Fund Management LLC Greenwich, CT196KShares$1.41 Million0.01% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $180M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...